Alnylam Pharmaceuticals Inc (Symbol: ALNY) shares have recently surpassed the average analyst 12-month target price of $207.84, trading at $212.01 per share. Analysts are now faced with either downgrading the stock on valuation or adjusting their target prices higher due to this development.
There are currently 19 analyst targets for Alnylam within the Zacks coverage universe, ranging from a low of $97.00 to a high of $430.00, with a standard deviation of $63.017. The recent ratings include 11 strong buy, 2 buy, and 5 hold ratings, with no sell or strong sell ratings reported. The average rating stands at 1.67, indicating a general optimism among analysts.
